Go Pro
→ Why This Small AI Company Holds 150 Patents (From Brownstone Research) (Ad)tc pixel Free RGC Stock Alerts

Regencell Bioscience (RGC) Competitors

Regencell Bioscience logo
$5.79 -0.17 (-2.85%)
Closing price 04:00 PM Eastern
Extended Trading
$5.84 +0.05 (+0.92%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

RGC vs. CORT, ELAN, AXSM, RDY, and CRNX

Should you buy Regencell Bioscience stock or one of its competitors? Regencell Bioscience's main competitors and comparable companies include Corcept Therapeutics (CORT), Elanco Animal Health (ELAN), Axsome Therapeutics (AXSM), Dr. Reddy's Laboratories (RDY), and Crinetics Pharmaceuticals (CRNX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Regencell Bioscience compare to Corcept Therapeutics?

Regencell Bioscience (NASDAQ:RGC) and Corcept Therapeutics (NASDAQ:CORT) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings.

0.1% of Regencell Bioscience shares are held by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are held by institutional investors. 2.0% of Regencell Bioscience shares are held by company insiders. Comparatively, 20.7% of Corcept Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Corcept Therapeutics has a consensus target price of $138.17, indicating a potential upside of 25.28%. Given Corcept Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Corcept Therapeutics is more favorable than Regencell Bioscience.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Regencell Bioscience
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Corcept Therapeutics
1 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.50

Regencell Bioscience has a beta of 1.45, indicating that its share price is 45% more volatile than the broader market. Comparatively, Corcept Therapeutics has a beta of 0.45, indicating that its share price is 55% less volatile than the broader market.

In the previous week, Corcept Therapeutics had 27 more articles in the media than Regencell Bioscience. MarketBeat recorded 27 mentions for Corcept Therapeutics and 0 mentions for Regencell Bioscience. Corcept Therapeutics' average media sentiment score of 0.73 beat Regencell Bioscience's score of 0.00 indicating that Corcept Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Regencell Bioscience Neutral
Corcept Therapeutics Positive

Corcept Therapeutics has higher revenue and earnings than Regencell Bioscience.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regencell BioscienceN/AN/A-$3.58MN/AN/A
Corcept Therapeutics$761.41M15.66$99.65M$0.42262.60

Corcept Therapeutics has a net margin of 6.52% compared to Regencell Bioscience's net margin of 0.00%. Corcept Therapeutics' return on equity of 8.26% beat Regencell Bioscience's return on equity.

Company Net Margins Return on Equity Return on Assets
Regencell BioscienceN/A N/A N/A
Corcept Therapeutics 6.52%8.26%6.45%

Summary

Corcept Therapeutics beats Regencell Bioscience on 12 of the 13 factors compared between the two stocks.

How does Regencell Bioscience compare to Elanco Animal Health?

Regencell Bioscience (NASDAQ:RGC) and Elanco Animal Health (NYSE:ELAN) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, dividends and analyst recommendations.

In the previous week, Elanco Animal Health had 10 more articles in the media than Regencell Bioscience. MarketBeat recorded 10 mentions for Elanco Animal Health and 0 mentions for Regencell Bioscience. Elanco Animal Health's average media sentiment score of 0.66 beat Regencell Bioscience's score of 0.00 indicating that Elanco Animal Health is being referred to more favorably in the news media.

Company Overall Sentiment
Regencell Bioscience Neutral
Elanco Animal Health Positive

Elanco Animal Health has a consensus price target of $29.09, indicating a potential upside of 29.92%. Given Elanco Animal Health's stronger consensus rating and higher possible upside, analysts plainly believe Elanco Animal Health is more favorable than Regencell Bioscience.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Regencell Bioscience
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Elanco Animal Health
1 Sell rating(s)
2 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.77

Regencell Bioscience has higher earnings, but lower revenue than Elanco Animal Health.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regencell BioscienceN/AN/A-$3.58MN/AN/A
Elanco Animal Health$4.72B2.37-$232M-$0.41N/A

Regencell Bioscience has a net margin of 0.00% compared to Elanco Animal Health's net margin of -3.96%. Elanco Animal Health's return on equity of 8.13% beat Regencell Bioscience's return on equity.

Company Net Margins Return on Equity Return on Assets
Regencell BioscienceN/A N/A N/A
Elanco Animal Health -3.96%8.13%3.99%

Regencell Bioscience has a beta of 1.45, meaning that its share price is 45% more volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.68, meaning that its share price is 68% more volatile than the broader market.

0.1% of Regencell Bioscience shares are owned by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are owned by institutional investors. 2.0% of Regencell Bioscience shares are owned by company insiders. Comparatively, 1.1% of Elanco Animal Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Elanco Animal Health beats Regencell Bioscience on 11 of the 14 factors compared between the two stocks.

How does Regencell Bioscience compare to Axsome Therapeutics?

Regencell Bioscience (NASDAQ:RGC) and Axsome Therapeutics (NASDAQ:AXSM) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability, earnings and media sentiment.

Axsome Therapeutics has a consensus target price of $267.60, suggesting a potential upside of 28.79%. Given Axsome Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Axsome Therapeutics is more favorable than Regencell Bioscience.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Regencell Bioscience
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Axsome Therapeutics
1 Sell rating(s)
2 Hold rating(s)
17 Buy rating(s)
2 Strong Buy rating(s)
2.91

In the previous week, Axsome Therapeutics had 10 more articles in the media than Regencell Bioscience. MarketBeat recorded 10 mentions for Axsome Therapeutics and 0 mentions for Regencell Bioscience. Axsome Therapeutics' average media sentiment score of 0.65 beat Regencell Bioscience's score of 0.00 indicating that Axsome Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Regencell Bioscience Neutral
Axsome Therapeutics Positive

Regencell Bioscience has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -24.68%. Regencell Bioscience's return on equity of 0.00% beat Axsome Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Regencell BioscienceN/A N/A N/A
Axsome Therapeutics -24.68%-265.55%-28.10%

Regencell Bioscience has a beta of 1.45, indicating that its stock price is 45% more volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.71, indicating that its stock price is 29% less volatile than the broader market.

Regencell Bioscience has higher earnings, but lower revenue than Axsome Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regencell BioscienceN/AN/A-$3.58MN/AN/A
Axsome Therapeutics$638.50M17.05-$183.17M-$3.75N/A

0.1% of Regencell Bioscience shares are owned by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are owned by institutional investors. 2.0% of Regencell Bioscience shares are owned by company insiders. Comparatively, 20.6% of Axsome Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Axsome Therapeutics beats Regencell Bioscience on 9 of the 14 factors compared between the two stocks.

How does Regencell Bioscience compare to Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories (NYSE:RDY) and Regencell Bioscience (NASDAQ:RGC) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment and institutional ownership.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dr. Reddy's Laboratories
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Regencell Bioscience
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Dr. Reddy's Laboratories has higher revenue and earnings than Regencell Bioscience.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dr. Reddy's Laboratories$3.58B2.84$456M$0.4427.71
Regencell BioscienceN/AN/A-$3.58MN/AN/A

In the previous week, Dr. Reddy's Laboratories had 5 more articles in the media than Regencell Bioscience. MarketBeat recorded 5 mentions for Dr. Reddy's Laboratories and 0 mentions for Regencell Bioscience. Dr. Reddy's Laboratories' average media sentiment score of 0.53 beat Regencell Bioscience's score of 0.00 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the media.

Company Overall Sentiment
Dr. Reddy's Laboratories Positive
Regencell Bioscience Neutral

3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. Comparatively, 0.1% of Regencell Bioscience shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Comparatively, 2.0% of Regencell Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Dr. Reddy's Laboratories has a beta of 0.28, meaning that its stock price is 72% less volatile than the broader market. Comparatively, Regencell Bioscience has a beta of 1.45, meaning that its stock price is 45% more volatile than the broader market.

Dr. Reddy's Laboratories has a net margin of 10.15% compared to Regencell Bioscience's net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 9.49% beat Regencell Bioscience's return on equity.

Company Net Margins Return on Equity Return on Assets
Dr. Reddy's Laboratories10.15% 9.49% 6.32%
Regencell Bioscience N/A N/A N/A

Summary

Dr. Reddy's Laboratories beats Regencell Bioscience on 9 of the 10 factors compared between the two stocks.

How does Regencell Bioscience compare to Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals (NASDAQ:CRNX) and Regencell Bioscience (NASDAQ:RGC) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment and institutional ownership.

98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. Comparatively, 0.1% of Regencell Bioscience shares are held by institutional investors. 3.8% of Crinetics Pharmaceuticals shares are held by insiders. Comparatively, 2.0% of Regencell Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Crinetics Pharmaceuticals currently has a consensus target price of $81.00, indicating a potential downside of 4.65%. Given Crinetics Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Crinetics Pharmaceuticals is more favorable than Regencell Bioscience.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Crinetics Pharmaceuticals
1 Sell rating(s)
11 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.24
Regencell Bioscience
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Crinetics Pharmaceuticals' average media sentiment score of 0.00 equaled Regencell Bioscience'saverage media sentiment score.

Company Overall Sentiment
Crinetics Pharmaceuticals Neutral
Regencell Bioscience Neutral

Crinetics Pharmaceuticals has a beta of 0.08, meaning that its stock price is 92% less volatile than the broader market. Comparatively, Regencell Bioscience has a beta of 1.45, meaning that its stock price is 45% more volatile than the broader market.

Regencell Bioscience has a net margin of 0.00% compared to Crinetics Pharmaceuticals' net margin of -1,189.88%. Regencell Bioscience's return on equity of 0.00% beat Crinetics Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Crinetics Pharmaceuticals-1,189.88% -44.22% -39.77%
Regencell Bioscience N/A N/A N/A

Regencell Bioscience has lower revenue, but higher earnings than Crinetics Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Crinetics Pharmaceuticals$7.70M1,170.54-$465.32M-$5.04N/A
Regencell BioscienceN/AN/A-$3.58MN/AN/A

Summary

Crinetics Pharmaceuticals beats Regencell Bioscience on 6 of the 11 factors compared between the two stocks.

Get Regencell Bioscience News Delivered to You Automatically

Sign up to receive the latest news and ratings for RGC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RGC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RGC vs. The Competition

Export
MetricRegencell BiosciencePharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$2.95B$12.53B$7.26B$13.13B
Dividend YieldN/A2.63%2.57%12.94%
P/E RatioN/A792.21273.8025.39
Price / SalesN/A945.09692.79108.47
Price / CashN/A88.4477.4251.66
Price / Book579.0010.4910.456.33
Net Income-$3.58M$2.81B$3.48B$358.24M
7 Day Performance2.66%2.83%0.88%1.20%
1 Month Performance6.04%3.30%0.03%-2.04%
1 Year Performance-61.78%3.58%18.28%5.41%

Regencell Bioscience Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RGC
Regencell Bioscience
0.1343 of 5 stars		$5.79
-2.9%		N/A-61.8%$2.95BN/AN/A10
CORT
Corcept Therapeutics
4.0159 of 5 stars		$115.70
+1.5%		$138.17
+19.4%		+52.8%$12.32B$761.41M275.48300
ELAN
Elanco Animal Health
4.1521 of 5 stars		$23.55
-1.8%		$29.09
+23.5%		+23.3%$11.98B$4.72BN/A9,400
AXSM
Axsome Therapeutics
3.7947 of 5 stars		$210.63
+1.4%		$267.60
+27.0%		+83.7%$10.89B$638.50MN/A380
RDY
Dr. Reddy's Laboratories
1.6764 of 5 stars		$11.89
+0.0%		N/A-18.1%$9.92B$3.58B27.0127,527

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:RGC) was last updated on 9/18/2026 by MarketBeat.com Staff.
From Our Partners
$40,000,000,000,000
The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...
American Alternative | Sponsoredtc pixel
A “bloodbath” Is Coming
Reports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...
TradeSmith | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel
Shocking new footage just released
Gerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...
Digest Publishing | Sponsoredtc pixel
Iran War WARNING: Something Just Changed
A powerful Middle Eastern government is reportedly asking Trump for U.S. military help against Iran backed for...
Banyan Hill Publishing | Sponsoredtc pixel
BlackRock, Vanguard... and a 2.8 million-share buyback
Management just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...
Monument Traders Alliance | Sponsoredtc pixel
Why I went to Mount Rushmore
A small miner just hit on gold in the hills surrounding Mount Rushmore, thanks to a breakthrough new technolog...
Stansberry Research | Sponsoredtc pixel
My next big call (under $1)
17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of...
Crypto 101 Media | Sponsoredtc pixel